Straits Times Index
3,141.70 -41.91 (-1.32%) Nikkei
38,471.20 -761.60 (-1.94%) Hang Seng
16,268.38 -332.08 (-2.00%) FTSE 100
7,861.55 -103.98 (-1.31%) Bitcoin USD
63,564.27 -2,766.39 (-4.17%) CMC Crypto 200
885.54 0.00 (0.00%)
REGN Jun 2024 760.000 call
| Previous close | 211.68 |
| Open | 211.68 |
| Bid | 222.40 |
| Ask | 231.00 |
| Strike | 760.00 |
| Expiry date | 2024-06-21 |
| Day's range | 211.68 - 211.68 |
| Contract range | N/A |
| Volume | |
| Open interest | 26 |
Yahoo FinanceAntitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.
- Reuters
UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation
Regeneron Pharmaceuticals said on Monday it seeks to defend against U.S. Department of Justice's complaint that alleged the company misreported the average sales price of its macular degeneration drug Eylea. "Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
ReutersRegeneron to defend against DOJ complaint on drug-price manipulation
"Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
